News
![UnitedHealth Group: Für die Zukunft muss sich der Konzern etwas einfallen lassen](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
UnitedHealth Group: Für die Zukunft muss sich der Konzern etwas einfallen lassen
![Evotec: Global Player der Biotech](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
Evotec: Global Player der Biotech
![Pfizer steigert Umsatz und Ergebnis](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
Pfizer steigert Umsatz und Ergebnis
![Johnson & Johnson: Wieder auf Wachstumskurs?](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Johnson & Johnson: Wieder auf Wachstumskurs?
![Johnson & Johnson steigert die Umsatzerlöse](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Johnson & Johnson steigert die Umsatzerlöse
![Pfizer langt ordentlich zu!](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Pfizer langt ordentlich zu!
![Pfizer: Ganz stark!](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Pfizer: Ganz stark!
![Der Biotech-Sektor im Aufwind und was das mit dem geplatzten Pfizer/Allergan-Deal zu tun hat](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
Der Biotech-Sektor im Aufwind und was das mit dem geplatzten Pfizer/Allergan-Deal zu tun hat
![Pfizer/ Allergan: Was geht denn da ab?](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
Pfizer/ Allergan: Was geht denn da ab?
![Why Walgreens Boots Alliance Plunged Today: https://g.foolcdn.com/editorial/images/788738/gettyimages-1340435722.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMTRGYlE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--206750eb0d4915cf4f09eaddbf67442181898138/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/gettyimages-1340435722.jpg?locale=us)
Why Walgreens Boots Alliance Plunged Today
Shares of beleaguered drug store and pharmacy chain Walgreens Boots Alliance (NASDAQ: WBA) fell 8.4% on Tuesday as of 3:22 p.m. ET.
The reason for the drop today appears to be twofold: One, Pfizer
![Is Pfizer Stock Still a Buy After an Unexpected Setback?: https://g.foolcdn.com/editorial/images/788199/frustrated-investor-at-computers.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNXNEYlE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--2520ebaebfcf2f2886557c7f0c81ae965d62bd04/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/frustrated-investor-at-computers.jpg?locale=us)
Is Pfizer Stock Still a Buy After an Unexpected Setback?
With Pfizer (NYSE: PFE) stock badly underperforming the market over the past three years, falling by 32% while the market rose by close to the same amount, the last thing shareholders want to hear
![Want $2,000 in Annual Dividends? Invest $30,000 in These 3 High-Yielding Stocks: https://g.foolcdn.com/editorial/images/787585/a-person-counting-money-in-their-living-room.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBK2NCYlE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--ff97d87cb6391750c73bf50f9c9cd318d5465e1c/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/a-person-counting-money-in-their-living-room.jpg?locale=us)
Want $2,000 in Annual Dividends? Invest $30,000 in These 3 High-Yielding Stocks
Dividend stocks can be a great source of cash flow for your portfolio. You don't need to settle for stocks that pay just a few percentage points, either. Some fairly safe, high-yielding stocks pay
![Pfizer and BioNTech's Combo Shot Missed the Mark. Is It Time to Sell?: https://g.foolcdn.com/editorial/images/787605/investor-looking-at-charts-on-a-computer-with-light-reflecting-off-their-glasses.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBLy83YkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--155d71a20356d6aec0dda8434bcb9edea9d0cc98/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/investor-looking-at-charts-on-a-computer-with-light-reflecting-off-their-glasses.jpg?locale=us)
Pfizer and BioNTech's Combo Shot Missed the Mark. Is It Time to Sell?
Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) recently fell behind in their race with Moderna (NASDAQ: MRNA) to develop new combination shots that could be worth billions in annual sales. Top-line
![Is Pfizer Stock Ready to Bounce Back?: https://g.foolcdn.com/editorial/images/785773/doctor-with-patient-talking.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNXI3YkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--0574bb0ba77474f1cf447105dc97f05fce537b67/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/doctor-with-patient-talking.jpg?locale=us)
Is Pfizer Stock Ready to Bounce Back?
Pharmaceutical giant Pfizer (NYSE: PFE) has been in a bit of a freefall since early 2022, with shares down by 46%. Pfizer's revenue and earnings dropped off a cliff along with its
![Why Pfizer Stock Slumped on Friday: https://g.foolcdn.com/editorial/images/787555/person-receiving-a-vaccine-shot.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBKzc2YkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--34c01122defbfafad4e704cd55b1609306dc925e/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/person-receiving-a-vaccine-shot.jpg?locale=us)
Why Pfizer Stock Slumped on Friday
In the thick of the coronavirus pandemic several years ago, any positive news from a developer of COVID-19 vaccines or drugs would have been met with a surge of buying in its stock. We're not in
![Prediction: Buying Biotech and Pharma Stocks During This Sell-Off Will Be a Smart Move: https://g.foolcdn.com/editorial/images/786305/investor-sitting-at-computer-with-pen.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBL0gxYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--db4f2e10170cfd2fe16fb822f6cce2ad635532a6/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/investor-sitting-at-computer-with-pen.jpg?locale=us)
Prediction: Buying Biotech and Pharma Stocks During This Sell-Off Will Be a Smart Move
The market is a bit jittery right now thanks to a confluence of factors, including a weaker-than-anticipated U.S. jobs report, international geopolitical issues, and foreign currency disruptions --
![3 Reliable Dividend Stocks With Yields Above 5% That You Can Buy With $100 Now: https://g.foolcdn.com/editorial/images/786807/investor-with-computer-getty.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMXYxYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--42666b54f2ae4b359a336ef7384879aed8864a3e/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/investor-with-computer-getty.jpg?locale=us)
3 Reliable Dividend Stocks With Yields Above 5% That You Can Buy With $100 Now
Would you like to improve your passive income stream but don't have a lot of extra cash to throw around? If so, I have great news: These days, $100 is all it takes to acquire a share of three top
![Is Pfizer Stock a Buy Now After Earnings?: https://g.foolcdn.com/editorial/images/786395/pfizer-bullish-stock-outlook-2024.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeUQxYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--eea01b0675ac437458b6ed64c00f49609875860b/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/pfizer-bullish-stock-outlook-2024.jpg?locale=us)
Is Pfizer Stock a Buy Now After Earnings?
While the COVID-19 pandemic is an increasingly distant memory for most investors, Pfizer (NYSE: PFE) has struggled to move past the overhang of record vaccine sales and earnings in 2021 and 2022
![Should Pfizer's Strong Quarter Calm Investor Concerns About the Stock?: https://g.foolcdn.com/editorial/images/785827/a-team-of-scientists-reviewing-results-in-a-lab.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMEh5YkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--2d1f597bf8ca20fc14aab46284160a5b88768ddb/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/a-team-of-scientists-reviewing-results-in-a-lab.jpg?locale=us)
Should Pfizer's Strong Quarter Calm Investor Concerns About the Stock?
Demand for COVID-19 vaccines and drugs has been fading for a while now. And that has put a big dent in Pfizer's (NYSE: PFE) sales and profit numbers. On top of that, the stock is also facing
![3 Unstoppable Dividend Stocks Yielding More Than 4% for Income-Seeking Investors to Buy in August and Hold Forever: https://g.foolcdn.com/editorial/images/785951/investment-advisor-getty.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeER1YkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--8e96d8e9046c41e4befcd64a551bd609fffb8336/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/investment-advisor-getty.jpg?locale=us)
3 Unstoppable Dividend Stocks Yielding More Than 4% for Income-Seeking Investors to Buy in August and Hold Forever
The past week has been a rotten one for most portfolios. On Monday, Aug. 5, the benchmark S&P 500 index began the trading session about 3% lower. That led the benchmark index to a loss of about 9.4%
![Is This Decision by Pfizer Bad News for Eli Lilly?: https://g.foolcdn.com/editorial/images/785370/gettyimages-1292931102.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOFByYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--00720586945ea559e9162b073a0f9b2a4546705b/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/gettyimages-1292931102.jpg?locale=us)
Is This Decision by Pfizer Bad News for Eli Lilly?
Eli Lilly (NYSE: LLY) stock has soared by double digits over the past year -- and for good reason. The pharma giant sells two of the most sought-after drugs today, weight loss treatments Mounjaro
![Is Pfizer Winning Its $43 Billion Bet?: https://g.foolcdn.com/editorial/images/785318/gettyimages-two-researchers-work-in-a-lab.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBN3ZxYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--07febf00bcb6d1d84d5bc5ddaec9ad17a443cae3/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/gettyimages-two-researchers-work-in-a-lab.jpg?locale=us)
Is Pfizer Winning Its $43 Billion Bet?
Pfizer (NYSE: PFE) is one of the most successful pharmaceutical companies ever. In 2022, it brought in more than $100 billion in revenue -- a record for itself and for the entire industry. Of
![Pfizer Just Confirmed It's a Dividend Investor's Dream Stock: https://g.foolcdn.com/editorial/images/785266/pfizer_logo_on_glass_pfe.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOHpvYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--59f3bdd4666a52f0b86fc0bba766102e7a003576/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/pfizer_logo_on_glass_pfe.jpg?locale=us)
Pfizer Just Confirmed It's a Dividend Investor's Dream Stock
Pfizer (NYSE: PFE) has been a nightmare for many investors in recent years. At one point earlier this year, the big pharma stock was nearly 60% below its peak set in late 2021.
However, the
![Bull Market Buys: 2 Growth Stocks to Own for the Long Run: https://g.foolcdn.com/editorial/images/784953/astonished-shocked-coffee-newspaper.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOURvYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--44208ae94e035aa3b3f64c6548d6e688b7af96ce/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/astonished-shocked-coffee-newspaper.jpg?locale=us)
Bull Market Buys: 2 Growth Stocks to Own for the Long Run
Investors who buy stocks through both bull and bear markets are the ones who tend to benefit more in the long term because they are growing their portfolios consistently. But a bull market does seem
![Pfizer to Buy a GLP-1 Drugmaker? Here's Why You Shouldn't Count on That Happening: https://g.foolcdn.com/editorial/images/784780/a-doctor-using-a-scale-to-measure-a-persons-weight.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOFhvYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--efd6e40d83f6673bc7d9f7907b1a242f2d24c80a/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/a-doctor-using-a-scale-to-measure-a-persons-weight.jpg?locale=us)
Pfizer to Buy a GLP-1 Drugmaker? Here's Why You Shouldn't Count on That Happening
The anti-obesity drug market could be worth a staggering $100 billion, according to some analysts. That's a huge growth opportunity, and it's a reason why many top drugmakers in the world are